Nerve Gas Antidote Autoinjector Gets Green Light for Cheap Generics
Published Date: 10/6/2026
Notice
Summary
The FDA has confirmed that the Pralidoxime Chloride autoinjector was not taken off the market because of safety or effectiveness problems. This means generic versions can now be approved, making it easier and potentially cheaper for people who need this medicine. Patients, healthcare providers, and drug makers can expect more options soon without any safety worries.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Pralidoxime Autoinjector Approvals Allowed
FDA determined that PRALIDOXIME CHLORIDE (AUTOINJECTOR) solution, 600 mg/2 mL (300 mg/mL), was not withdrawn for reasons of safety or effectiveness. Because of that finding, the Agency said it may approve abbreviated new drug applications (ANDAs) for this product if the applicants meet all other legal and regulatory requirements.
No Safety/Effectiveness Withdrawal Found
FDA reviewed its records, literature, and postmarketing adverse event data and found no information showing that PRALIDOXIME CHLORIDE (AUTOINJECTOR), 600 mg/2 mL (300 mg/mL), was withdrawn from sale for reasons of safety or effectiveness. The product (NDA 018986, initially approved April 26, 1983) will remain listed in the Orange Book's Discontinued Drug Product List as discontinued for reasons other than safety or effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2026-20438, Privacy Act of 1974; Systems of Records
The Nuclear Regulatory Commission is updating 13 records systems to better protect your personal info and clarify how they handle data. Most changes are small fixes, but four systems got big updates that need your feedback by November 5, 2026. These updates help keep your info safe and the rules clear, with no extra costs involved.
Next: 2026-20446, Agency Information Collection Activities Under OMB Review
The Commodity Futures Trading Commission is asking for public feedback on a new paperwork plan that affects traders and companies dealing with futures. They want to make sure the info they collect is useful and not too costly or time-consuming. You’ve got until November 5, 2026, to share your thoughts online or by mail—so don’t miss out!